siRNA candidate enters the clinic

Article

SR Pharma has launched a Phase I clinical trial of RTP-801i.

SR Pharma has launched a Phase I clinical trial of RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma.

RTP-801i is based on Atugen's proprietary siRNA technology that modifies the expression of one specific gene target involved in the progression of age-related macular degeneration (AMD).

Pfizer, who licensed the product in September of last year, is funding the trial.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A close-up photo of a woman with red, inflamed eyes. Her eye is swollen and blood vessels are visible. Image credit: ©Janeberry – stock.adobe.com

Shifting the narrative around dry eye disease

Hattie Hayes;Emanuela Aragona, MD, PhD
February 6th 2025
Article

A qualitative study method illuminates patients’ fears for the future

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

An illustration of enlarged blood cells and a vial labeled "COVID-19." Image credit: ©Mongkolchon – stock.adobe.com

COVID-19 may impact anatomy of retina and functional vision

Lynda Charters
February 5th 2025
Article

Choroidal and retinal changes were examined with optical coherence tomography angiography

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A child looks at the camera. She has on red glasses. Image credit: ©Annashou – stock.adobe.com

A new home treatment for amblyopia

Lynda Charters;Reviewed by Tamara Wygnanski-Jaffe, MD; and Nicholas Sala, DO
February 4th 2025
Article

Binocular eye tracking could serve as alternative to patching and provide visual acuity gains with heightened adherence rates

A person in a suit sits at a laptop. A US Food and Drug Administration logo and approval badge are superimposed over the image. Image credit: ©Nirusmee – stock.adobe.com

US FDA approves continuous delivery ranibizumab treatment (Susvimo, Genentech) for diabetic macular oedema

Martin David Harp
February 4th 2025
Article

Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States

© 2025 MJH Life Sciences

All rights reserved.